Invo Fertility, INC. (IVF) — SEC Filings

Overview

Invo Fertility, INC. (IVF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Dec 30, 2025: INVO Fertility, Inc. (formerly NAYA Biosciences, Inc.) filed a DEFA14A proxy statement on December 30, 2025. The filing indicates no fee was required for this submission. The company, previously known as INVO Bioscience, Inc., is incorporated in Nevada and operates in the Surgical & Medical Instrume

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 6 bearish, 42 neutral, 2 mixed. The dominant filing sentiment for Invo Fertility, INC. is neutral.

Filing Type Overview

Invo Fertility, INC. (IVF) has filed 4 DEFA14A, 3 DEF 14A, 30 8-K, 3 10-Q, 2 S-1, 2 10-K/A, 2 8-K/A, 1 10-K, 2 S-1/A, 1 SC 13G/A with the SEC between Oct 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

• INVO Fertility Files Proxy Statement — DEFA14A · Dec 30, 2025 Risk: low
  INVO Fertility, Inc. (formerly NAYA Biosciences, Inc.) filed a DEFA14A proxy statement on December 30, 2025. The filing indicates no fee was required for this s
• INVO Fertility Seeks Massive Share Increase, Warrant Approval — DEF 14A · Dec 18, 2025 Risk: high
  INVO Fertility, Inc. (IVF) is holding a Special Meeting on January 22, 2026, to address several critical proposals impacting its capital structure and equity in
• 8-K Filing — 8-K · Dec 17, 2025
• INVO Fertility Files 8-K: Material Agreement, Equity Sales — 8-K · Dec 5, 2025 Risk: medium
  On December 2, 2025, INVO Fertility, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and
• 8-K Filing — 8-K · Dec 3, 2025
• INVO Fertility's Losses Mount Amid Strategic Divestitures — 10-Q · Nov 17, 2025 Risk: high
  INVO Fertility, Inc. (IVF) reported a significant net loss of $25,333,069 for the nine months ended September 30, 2025, a substantial increase from the $5,472,3
• INVO Fertility Reports Unregistered Equity Sale — 8-K · Oct 22, 2025 Risk: medium
  On October 16, 2025, INVO Fertility, Inc. reported an unregistered sale of equity securities. The filing does not disclose the specific number of shares sold or
• INVO Fertility S-1: FNL to Resell 8.3M Shares, IVF Refocuses on Clinics — S-1 · Oct 14, 2025 Risk: high
  INVO Fertility, Inc. (IVF) filed an S-1 on October 14, 2025, for the resale of up to 8,345,774 shares of common stock by Five Narrow Lane LP (FNL). These shares
• INVO Fertility Files 8-K on Equity Sale — 8-K · Oct 10, 2025 Risk: medium
  On October 6, 2025, INVO Fertility, Inc. filed an 8-K report detailing the unregistered sale of equity securities. The company, formerly known as NAYA Bioscienc
• INVO Fertility, Inc. Files 8-K with Material Agreement — 8-K · Oct 3, 2025 Risk: medium
  On September 30, 2025, INVO Fertility, Inc. entered into a Material Definitive Agreement. The company also reported on Unregistered Sales of Equity Securities a
• INVO Fertility, Inc. Files 8-K with Material Agreement — 8-K · Sep 29, 2025 Risk: medium
  On September 29, 2025, INVO Fertility, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities a
• INVO Fertility, Inc. Files 8-K for Material Agreement — 8-K · Sep 26, 2025 Risk: medium
  On September 22, 2025, INVO Fertility, Inc. entered into a Material Definitive Agreement. The filing also includes financial statements and exhibits related to
• INVO Fertility Reports Unregistered Equity Sale — 8-K · Sep 12, 2025 Risk: medium
  On September 8, 2025, INVO Fertility, Inc. reported an unregistered sale of equity securities. The filing does not disclose the specific number of shares sold,
• INVO Fertility, Inc. Reports Change in Certifying Accountant — 8-K · Sep 5, 2025 Risk: low
  INVO Fertility, Inc. filed an 8-K on September 3, 2025, reporting changes in its certifying accountant. The company, formerly known as NAYA Biosciences, Inc. an
• INVO Fertility Files 8-K: Material Agreements & Equity Updates — 8-K · Aug 22, 2025 Risk: medium
  On August 21, 2025, INVO Fertility, Inc. entered into a Material Definitive Agreement. The company also reported on Unregistered Sales of Equity Securities and
• INVO Fertility Files 8-K with Financials — 8-K · Aug 15, 2025 Risk: low
  On August 14, 2025, INVO Fertility, Inc. filed an 8-K report detailing its financial results and operations. The company, formerly known as NAYA Biosciences, In
• INVO Fertility's Net Loss Widens to $22.7M Amid NTI Divestiture — 10-Q · Aug 14, 2025 Risk: high
  INVO Fertility, Inc. (IVF) reported a significant net loss of $22.69 million for the six months ended June 30, 2025, a substantial increase from the $3.84 milli
• INVO Fertility Reports Unregistered Equity Sale — 8-K · Aug 1, 2025 Risk: medium
  On July 28, 2025, INVO Fertility, Inc. filed an 8-K report detailing an unregistered sale of equity securities. The company, formerly known as NAYA Biosciences,
• INVO Fertility Files 8-K on Equity Sales and Shareholder Votes — 8-K · Jul 23, 2025 Risk: medium
  On July 17, 2025, INVO Fertility, Inc. reported on the unregistered sale of equity securities and the submission of matters to a vote of security holders. The c
• INVO Fertility, Inc. Amends Articles of Incorporation — 8-K · Jul 21, 2025 Risk: low
  On July 17, 2025, INVO Fertility, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation. The company, formerly known as NAYA Bioscience
• INVO Fertility Files Proxy Materials — DEFA14A · Jul 17, 2025 Risk: low
  INVO Fertility, Inc. filed a Definitive Additional Materials proxy statement on July 17, 2025. The filing relates to the company's proxy materials, indicating a
• INVO Fertility Approves 1-for-20 Reverse Stock Split — 8-K · Jul 10, 2025 Risk: medium
  On July 9, 2025, INVO Fertility, Inc. announced that its Board of Directors approved a reverse stock split of its common stock at a ratio of 1-for-20. This acti
• INVO Fertility Files 8-K: Material Agreement, Equity Sales — 8-K · Jul 1, 2025 Risk: medium
  On June 27, 2025, INVO Fertility, Inc. entered into a Material Definitive Agreement. The company also reported on unregistered sales of equity securities and am
• INVO Fertility Files 8-K on Security Holder Vote Matters — 8-K · Jun 25, 2025 Risk: medium
  On June 25, 2025, INVO Fertility, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, formerly known as NAYA
• INVO Fertility Files Proxy Materials — DEFA14A · Jun 23, 2025 Risk: low
  INVO Fertility, Inc. filed a Definitive Additional Materials proxy statement on June 23, 2025. This filing relates to the company's proxy materials, indicating
• INVO Fertility Completes NAYA Biosciences Asset Acquisition — 8-K · Jun 6, 2025 Risk: medium
  INVO Fertility, Inc. announced the completion of its acquisition of assets from NAYA Biosciences, Inc. on June 2, 2025. This strategic move aims to expand INVO
• INVO Fertility Leans on Equity Awards for Executive Incentives — DEF 14A · Jun 4, 2025 Risk: medium
  INVO Fertility, Inc. (IVF) filed its DEF 14A on June 4, 2025, outlining executive compensation and corporate governance for the fiscal year ended December 31, 2
• INVO Fertility Files 8-K: Agreements, Equity Sales, Officer Changes — 8-K · May 30, 2025 Risk: medium
  On May 23, 2025, INVO Fertility, Inc. filed an 8-K detailing several significant events. These include entering into a material definitive agreement, unregister
• INVO Fertility Files 8-K on Financials — 8-K · May 21, 2025 Risk: low
  INVO Fertility, Inc. filed an 8-K on May 21, 2025, reporting on events as of May 20, 2025. The filing pertains to Results of Operations and Financial Condition,
• INVO Fertility, Inc. Files Q1 2025 10-Q — 10-Q · May 20, 2025 Risk: low
  INVO Fertility, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as NAYA Biosciences, Inc. and INVO Bioscience, Inc., is in
• INVO Fertility Files 2024 Annual Report Amendment — 10-K/A · May 19, 2025 Risk: low
  INVO Fertility, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The company, formerly known as NAYA Bioscienc
• INVO Fertility Files 8-K/A Amendment — 8-K/A · May 2, 2025 Risk: medium
  INVO Fertility, Inc. filed an 8-K/A amendment on May 2, 2025, related to events occurring on April 30, 2025. The filing pertains to the entry into a material de
• INVO Fertility Files 2024 10-K — 10-K · Apr 30, 2025 Risk: low
  INVO Fertility, Inc. filed its 2024 10-K on April 30, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly NAYA Biosciences, Inc.,
• INVO Fertility Faces Delisting Concerns — 8-K · Apr 18, 2025 Risk: high
  INVO Fertility, Inc. filed an 8-K on April 18, 2025, reporting a notice of delisting or failure to satisfy continued listing rules. The company, formerly known
• NAYA Biosciences Reports Shareholder Vote Matters — 8-K · Apr 14, 2025 Risk: low
  NAYA Biosciences, Inc. filed an 8-K on April 14, 2025, reporting on matters submitted to a vote of security holders on April 9, 2025. The filing details the com
• NAYA Biosciences Faces Delisting Notice — 8-K · Mar 31, 2025 Risk: high
  NAYA Biosciences, Inc. filed an 8-K on March 25, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, formerly kno
• NAYA Biosciences Files 8-K with Corporate Updates — 8-K · Mar 24, 2025 Risk: low
  NAYA Biosciences, Inc. (formerly INVO Bioscience, Inc.) filed an 8-K on March 24, 2025, reporting events that occurred on March 18, 2025. The filing indicates c
• NAYA Biosciences Files 8-K: Other Events & Exhibits — 8-K · Mar 7, 2025 Risk: low
  On March 7, 2025, NAYA Biosciences, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific mat
• NAYA Biosciences Files Proxy Materials — DEFA14A · Feb 13, 2025 Risk: low
  NAYA Biosciences, Inc. filed a Definitive Additional Materials proxy statement on February 13, 2025. This filing relates to the company's proxy materials, which
• NAYA Biosciences Files DEF 14A for Executive Compensation — DEF 14A · Feb 11, 2025 Risk: medium
  NAYA Biosciences, Inc. filed a DEF 14A on February 11, 2025, detailing executive compensation and corporate governance matters for the fiscal year ending Decemb
• NAYA Biosciences Faces Delisting, Material Agreements — 8-K · Jan 16, 2025 Risk: high
  On January 10, 2025, NAYA Biosciences, Inc. filed an 8-K report detailing several significant events. These include entering into a material definitive agreemen
• NAYA Biosciences Files S-1/A Amendment — S-1/A · Jan 8, 2025 Risk: medium
  NAYA Biosciences, Inc. filed an S-1/A amendment on January 8, 2025, for its registration statement. The company, formerly known as INVO Bioscience, Inc., is inc
• NAYA Biosciences Files S-1/A Amendment — S-1/A · Jan 7, 2025 Risk: medium
  NAYA Biosciences, Inc. filed an S-1/A amendment on January 7, 2025, for its registration statement. The company, formerly known as INVO Bioscience, Inc., is inc
• NAYA Biosciences Files S-1 Registration — S-1 · Dec 17, 2024 Risk: medium
  NAYA Biosciences, Inc. filed an S-1 registration statement on December 17, 2024, to register securities under the Securities Act of 1933. The company, formerly
• NAYA Biosciences Files 8-K/A Amendment — 8-K/A · Dec 12, 2024 Risk: low
  NAYA Biosciences, Inc. filed an 8-K/A on December 12, 2024, to amend a previous filing concerning a material definitive agreement and financial statements. The
• NAYA Biosciences Files 2023 10-K/A Amendment — 10-K/A · Nov 19, 2024 Risk: medium
  NAYA Biosciences, Inc. filed an amendment (10-K/A) on November 19, 2024, for the fiscal year ending December 31, 2023. The company, formerly known as INVO Biosc
• SC 13G/A Filing — SC 13G/A · Nov 13, 2024
• NAYA Biosciences Files 8-K — 8-K · Nov 8, 2024 Risk: low
  NAYA Biosciences, Inc. filed an 8-K on November 8, 2024, reporting other events and financial statements and exhibits. The report covers events as of November 4
• INVO Bioscience Reports Material Agreements & Asset Changes — 8-K · Oct 15, 2024 Risk: medium
  INVO Bioscience, Inc. filed an 8-K on October 15, 2024, reporting several key events as of October 11, 2024. These include entering into a material definitive a
• INVO Bioscience Enters Material Agreement, Incurs Financial Obligation — 8-K · Oct 1, 2024 Risk: medium
  INVO Bioscience, Inc. entered into a Material Definitive Agreement on September 25, 2024, which also created a direct financial obligation for the registrant. T

Risk Profile

Risk Assessment: Of IVF's 47 recent filings, 7 were flagged as high-risk, 24 as medium-risk, and 16 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Invo Fertility, INC.'s most recent 10-Q filing (Nov 17, 2025):

• Revenue: $5,257,933
• Net Income: -$25,333,069
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $355,891
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Steven Shum
• Steve Shum
• Daniel Teper

Industry Context

INVO Fertility operates within the assisted reproductive technology (ART) and fertility services industry. This sector is characterized by increasing demand driven by delayed childbearing, advancements in treatment technologies, and growing awareness. However, it also faces challenges related to regulatory oversight, high treatment costs, and competition from established players and emerging technologies.

Top Tags

material-agreement (12) · equity-sale (10) · corporate-governance (8) · filing (7) · amendment (6) · corporate-action (5) · sec-filing (4) · corporate-update (3) · equity-securities (3) · company-name-change (3)

Key Numbers

• New authorized shares of Common Stock: 250,000,000 — Increased from 6,250,000, a 3,900% increase
• Current authorized shares of Common Stock: 6,250,000 — Baseline before proposed increase
• Shares for warrant exercise: 4,733,728 — Subject to adjustment, from a private placement on December 4, 2025
• Shares for 2019 Stock Incentive Plan: 1,000,000 — Approximately 10% of total issued and outstanding stock on a fully-diluted basis
• Beneficial ownership by directors and executive officers: 0.72% — Of outstanding voting capital as of Record Date
• Shares of Common Stock outstanding: 2,386,826 — As of the Record Date for quorum calculation
• Record Date: December 8, 2025 — For voting eligibility at the Special Meeting
• Special Meeting Date: January 22, 2026 — When stockholders will vote on proposals
• Net Loss: $25.3M — Increased from $5.5M in 2024, primarily due to discontinued operations.
• Cash Balance: $355.9K — Decreased from $619.5K at December 31, 2024, indicating significant cash burn.
• Net Cash Used in Operating Activities: $7.0M — Increased from $2.4M in 2024, highlighting operational cash drain.
• Total Revenue: $5.3M — Increased from $4.8M in 2024, driven by clinic revenue growth.
• Total Operating Expenses: $11.1M — Increased from $9.5M in 2024, including a $1.4M impairment loss.
• Loss on Discontinued Operations of NTI: $16.5M — Major contributor to the increased net loss for the period.
• Net Loss Increase: 362% — Percentage increase in net loss from 2024 to 2025 for the nine-month period.

Related Companies

IVOF

Frequently Asked Questions